MiMedx Group (NASDAQ: MDXG) and Neogen Corporation (NASDAQ:NEOG) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, risk, dividends, institutional ownership and profitability.

Volatility and Risk

MiMedx Group has a beta of 1.03, indicating that its stock price is 3% more volatile than the S&P 500. Comparatively, Neogen Corporation has a beta of 1.52, indicating that its stock price is 52% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and price targets for MiMedx Group and Neogen Corporation, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MiMedx Group 1 0 4 0 2.60
Neogen Corporation 0 2 0 0 2.00

MiMedx Group currently has a consensus price target of $14.20, suggesting a potential downside of 16.13%. Given MiMedx Group’s stronger consensus rating and higher probable upside, analysts plainly believe MiMedx Group is more favorable than Neogen Corporation.

Earnings and Valuation

This table compares MiMedx Group and Neogen Corporation’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
MiMedx Group $283.32 million 6.72 $32.97 million $0.19 89.11
Neogen Corporation $361.59 million 6.96 $79.64 million $1.14 57.74

Neogen Corporation has higher revenue and earnings than MiMedx Group. Neogen Corporation is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

53.7% of MiMedx Group shares are held by institutional investors. Comparatively, 85.5% of Neogen Corporation shares are held by institutional investors. 12.4% of MiMedx Group shares are held by company insiders. Comparatively, 4.7% of Neogen Corporation shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.


This table compares MiMedx Group and Neogen Corporation’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
MiMedx Group 7.48% 15.95% 11.13%
Neogen Corporation 12.11% 9.87% 8.80%

About MiMedx Group

MiMedx Group, Inc. is an integrated developer, processor and marketer of regenerative biomaterial products and bioimplants human placental tissue, skin and bone. The Company’s Regenerative Biomaterials segment includes the design, manufacture, and marketing of products and tissue processing services for the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental market categories. Its biomaterial platform technologies include AmnioFix, EpiFix, OrthoFlo, Physio, AlloBurn, and CollaFix. AmnioFix and EpiFix are its tissue technologies processed from human amniotic membrane derived from donated placentas. OrthoFlo is amniotic fluid-derived allograft for homologous use. Physio is a bone grafting material consists of bone tissue with no added carrier. CollaFix, its new brand, is its collagen fiber technology designed to mimic the natural composition, structure and mechanical properties of musculoskeletal tissues in order to augment their repair.

About Neogen Corporation

Neogen Corporation develops, manufactures and markets a range of products and services dedicated to food and animal safety. The Company operates through two segments: Food Safety and Animal Safety. The Food Safety segment produces and markets diagnostic test kits and related products used by food producers and processors to detect harmful natural toxins, foodborne bacteria, allergens and levels of general sanitation. The Animal Safety segment is primarily engaged in the production and marketing of products dedicated to animal health, including a range of consumable products marketed to veterinarians and animal health product distributors. The Animal Safety segment also provides genetic identification services. Additionally, the Animal Safety segment produces and markets rodenticides, disinfectants and insecticides to assist in the control of rodents and disease in and around agricultural, food production and other facilities.

Receive News & Ratings for MiMedx Group Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiMedx Group Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.